⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

ALKS News

Alkermes Inc. plc

Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025